How much profit has Rua Life Sciences made this year?
Rua Life Sciences has made -2.78 M GBP this year.
Rua Life Sciences Net Income 2024
Rua Life Sciences Net Income
-2.78 M GBP
Ticker
RUA.L
ISIN
GB0033360586
WKN
121857
In 2024, Rua Life Sciences's profit amounted to -2.78 M GBP, a 38.82% increase from the -2 M GBP profit recorded in the previous year.
The Rua Life Sciences Net Income history
| YEAR | NET INCOME (undefined GBP) |
|---|---|
| 2026e | 447.45 |
| 2025e | -1,022.75 |
| 2024e | -2,780.61 |
| 2023 | -2,003 |
| 2022 | -2,070 |
| 2021 | -1,450 |
| 2020 | -820 |
| 2019 | -610 |
| 2018 | -30 |
| 2017 | -180 |
| 2016 | -400 |
| 2015 | -230 |
| 2014 | -820 |
| 2013 | -540 |
| 2012 | 40 |
| 2011 | -2,500 |
| 2010 | -1,920 |
| 2009 | -1,250 |
| 2008 | -1,160 |
| 2007 | -2,120 |
| 2006 | -520 |
| 2005 | -1,870 |
| 2004 | 530 |
Rua Life Sciences Revenue, EBIT, Net Income GB0033360586 · 121857
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Rua Life Sciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Rua Life Sciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Rua Life Sciences’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Rua Life Sciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Rua Life Sciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Rua Life Sciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Rua Life Sciences’s growth potential.
Rua Life Sciences Revenue, EBIT and net profit per share
| Date | Rua Life Sciences Revenue | Rua Life Sciences EBIT | Rua Life Sciences Net Income |
|---|---|---|---|
| 2026e | 4.43 M undefined | 412,000 undefined | 447,454.75 undefined |
| 2025e | 3.4 M undefined | -1.13 M undefined | -1.02 M undefined |
| 2024e | 2.29 M undefined | -2.14 M undefined | -2.78 M undefined |
| 2023 | 2.18 M undefined | -2.31 M undefined | -2 M undefined |
| 2022 | 1.63 M undefined | -2.35 M undefined | -2.07 M undefined |
| 2021 | 1.53 M undefined | -1.55 M undefined | -1.45 M undefined |
| 2020 | 490,000 undefined | -940,000 undefined | -820,000 undefined |
| 2019 | 460,000 undefined | -630,000 undefined | -610,000 undefined |
| 2018 | 400,000 undefined | -290,000 undefined | -30,000 undefined |
| 2017 | 470,000 undefined | -190,000 undefined | -180,000 undefined |
| 2016 | 500,000 undefined | -330,000 undefined | -400,000 undefined |
| 2015 | 520,000 undefined | -150,000 undefined | -230,000 undefined |
| 2014 | 260,000 undefined | -430,000 undefined | -820,000 undefined |
| 2013 | 200,000 undefined | -760,000 undefined | -540,000 undefined |
| 2012 | 3.16 M undefined | 500,000 undefined | 40,000 undefined |
| 2011 | 1.57 M undefined | -2.14 M undefined | -2.5 M undefined |
| 2010 | 1.36 M undefined | -2.06 M undefined | -1.92 M undefined |
| 2009 | 1.26 M undefined | -1.54 M undefined | -1.25 M undefined |
| 2008 | 1.48 M undefined | -1.37 M undefined | -1.16 M undefined |
| 2007 | 280,000 undefined | -2.23 M undefined | -2.12 M undefined |
| 2006 | 1.43 M undefined | -670,000 undefined | -520,000 undefined |
| 2005 | 140,000 undefined | -2.08 M undefined | -1.87 M undefined |
| 2004 | 360,000 undefined | -2.19 M undefined | 530,000 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 360,000 GBP | -2.19 M GBP | 530,000 GBP |
| 2005 | 140,000 GBP | -2.08 M GBP | -1.87 M GBP |
| 2006 | 1.43 M GBP | -670,000 GBP | -520,000 GBP |
| 2007 | 280,000 GBP | -2.23 M GBP | -2.12 M GBP |
| 2008 | 1.48 M GBP | -1.37 M GBP | -1.16 M GBP |
| 2009 | 1.26 M GBP | -1.54 M GBP | -1.25 M GBP |
| 2010 | 1.36 M GBP | -2.06 M GBP | -1.92 M GBP |
| 2011 | 1.57 M GBP | -2.14 M GBP | -2.5 M GBP |
| 2012 | 3.16 M GBP | 500,000 GBP | 40,000 GBP |
| 2013 | 200,000 GBP | -760,000 GBP | -540,000 GBP |
| 2014 | 260,000 GBP | -430,000 GBP | -820,000 GBP |
| 2015 | 520,000 GBP | -150,000 GBP | -230,000 GBP |
| 2016 | 500,000 GBP | -330,000 GBP | -400,000 GBP |
| 2017 | 470,000 GBP | -190,000 GBP | -180,000 GBP |
| 2018 | 400,000 GBP | -290,000 GBP | -30,000 GBP |
| 2019 | 460,000 GBP | -630,000 GBP | -610,000 GBP |
| 2020 | 490,000 GBP | -940,000 GBP | -820,000 GBP |
| 2021 | 1.53 M GBP | -1.55 M GBP | -1.45 M GBP |
| 2022 | 1.63 M GBP | -2.35 M GBP | -2.07 M GBP |
| 2023 | 2.18 M GBP | -2.31 M GBP | -2 M GBP |
| 2024e | 2.29 M GBP | -2.14 M GBP | -2.78 M GBP |
| 2025e | 3.4 M GBP | -1.13 M GBP | -1.02 M GBP |
| 2026e | 4.43 M GBP | 412,000 GBP | 447,454.75 GBP |
Rua Life Sciences stock margins GB0033360586 · 121857
The Rua Life Sciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Rua Life Sciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Rua Life Sciences.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Rua Life Sciences's sales revenue. A higher gross margin percentage indicates that the Rua Life Sciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Rua Life Sciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Rua Life Sciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Rua Life Sciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Rua Life Sciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Rua Life Sciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Rua Life Sciences Margin History
| Rua Life Sciences Gross margin | Rua Life Sciences Profit margin | Rua Life Sciences EBIT margin | Rua Life Sciences Profit margin |
|---|---|---|---|
| 2026e | 82.19 % | 9.3 % | 10.1 % |
| 2025e | 82.19 % | -33.33 % | -30.09 % |
| 2024e | 82.19 % | -93.2 % | -121.32 % |
| 2023 | 82.19 % | -105.83 % | -91.92 % |
| 2022 | 83.44 % | -144.17 % | -126.99 % |
| 2021 | 81.7 % | -101.31 % | -94.77 % |
| 2020 | 82.19 % | -191.84 % | -167.35 % |
| 2019 | 82.19 % | -136.96 % | -132.61 % |
| 2018 | 82.19 % | -72.5 % | -7.5 % |
| 2017 | 82.19 % | -40.43 % | -38.3 % |
| 2016 | 82.19 % | -66 % | -80 % |
| 2015 | 82.19 % | -28.85 % | -44.23 % |
| 2014 | 100 % | -165.38 % | -315.38 % |
| 2013 | 100 % | -380 % | -270 % |
| 2012 | 86.08 % | 15.82 % | 1.27 % |
| 2011 | 77.07 % | -136.31 % | -159.24 % |
| 2010 | 72.06 % | -151.47 % | -141.18 % |
| 2009 | 90.48 % | -122.22 % | -99.21 % |
| 2008 | 86.49 % | -92.57 % | -78.38 % |
| 2007 | 42.86 % | -796.43 % | -757.14 % |
| 2006 | 83.92 % | -46.85 % | -36.36 % |
| 2005 | 78.57 % | -1,485.71 % | -1,335.71 % |
| 2004 | 91.67 % | -608.33 % | 147.22 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 91.67 % | -608.33 % | 147.22 % |
| 2005 | 78.57 % | -1,485.71 % | -1,335.71 % |
| 2006 | 83.92 % | -46.85 % | -36.36 % |
| 2007 | 42.86 % | -796.43 % | -757.14 % |
| 2008 | 86.49 % | -92.57 % | -78.38 % |
| 2009 | 90.48 % | -122.22 % | -99.21 % |
| 2010 | 72.06 % | -151.47 % | -141.18 % |
| 2011 | 77.07 % | -136.31 % | -159.24 % |
| 2012 | 86.08 % | 15.82 % | 1.27 % |
| 2013 | 100 % | -380 % | -270 % |
| 2014 | 100 % | -165.38 % | -315.38 % |
| 2015 | 82.19 % | -28.85 % | -44.23 % |
| 2016 | 82.19 % | -66 % | -80 % |
| 2017 | 82.19 % | -40.43 % | -38.3 % |
| 2018 | 82.19 % | -72.5 % | -7.5 % |
| 2019 | 82.19 % | -136.96 % | -132.61 % |
| 2020 | 82.19 % | -191.84 % | -167.35 % |
| 2021 | 81.7 % | -101.31 % | -94.77 % |
| 2022 | 83.44 % | -144.17 % | -126.99 % |
| 2023 | 82.19 % | -105.83 % | -91.92 % |
| 2024e | 82.19 % | -93.2 % | -121.32 % |
| 2025e | 82.19 % | -33.33 % | -30.09 % |
| 2026e | 82.19 % | 9.3 % | 10.1 % |
Rua Life Sciences Aktienanalyse
What does Rua Life Sciences do?
Rua Life Sciences PLC is a British company specializing in the development and manufacture of therapeutics and medical devices in the pharmaceutical industry. It was founded in 1999 by Dr. Ahmed Abdullah as Research Chemicals International. In 2007, it was renamed Rua Life Sciences PLC and has been listed on the London Stock Exchange since 2014. The business model of Rua Life Sciences PLC is the research and development of pharmaceuticals. The company invests in the discovery of new active substances and technologies that can be used to treat diseases. In addition, Rua Life Sciences PLC is also involved in the storage and transportation of pharmaceutical products. The product range of Rua Life Sciences PLC includes various areas such as oncology, neurology, ophthalmology, infectious diseases, and cardiovascular diseases. In oncology research, the company works on innovative approaches to the treatment of various types of cancer. This includes the development of drugs to combat breast cancer or lung cancer. In neurology, Rua Life Sciences PLC aims to develop new therapeutics for the treatment of diseases of the nervous system. This includes, among other things, drugs for the relief of Parkinson's or Alzheimer's. In the field of ophthalmology, the company researches drugs for the treatment of eye diseases such as macular degeneration, which leads to vision impairment in older people. This also includes testing new technologies such as the combination of drugs with special apparatus. In infectious diseases research, Rua Life Sciences PLC works on drugs to combat viruses and bacteria that can cause various diseases. This also includes the development of vaccines to counter epidemic outbreaks. Another important area for Rua Life Sciences PLC is research in the field of cardiovascular diseases. The company is working on drugs to treat hypertension, heart attacks, and other cardiovascular diseases. In addition to pharmaceutical products and therapeutics, Rua Life Sciences PLC also offers medical devices. These include blood glucose meters and medical inhalers used in the treatment of respiratory diseases. The company aims to help patients worldwide and save lives. It invests large sums in the research and development of therapeutics and medical devices to improve healthcare for humans and animals. Rua Life Sciences PLC collaborates with leading scientists and biomedical companies and maintains a network of partners around the world. Overall, Rua Life Sciences PLC is a company with a wide product range specializing in the manufacture of pharmaceuticals and medical devices. The company is committed to healing diseases and improving the health of people worldwide. Rua Life Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Rua Life Sciences's Profit Margins
The profit margins of Rua Life Sciences represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Rua Life Sciences's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Rua Life Sciences's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Rua Life Sciences's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Rua Life Sciences’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Rua Life Sciences stock
How has the profit developed compared to last year?
The profit has increased by 38.82% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Rua Life Sciences publish its earnings?
Rua Life Sciences publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Rua Life Sciences?
The profits of Rua Life Sciences are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Rua Life Sciences?
You can learn more about the earnings of Rua Life Sciences by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Rua Life Sciences pay?
Over the past 12 months, Rua Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Rua Life Sciences is expected to pay a dividend of 0 GBP.
What is the dividend yield of Rua Life Sciences?
The current dividend yield of Rua Life Sciences is .
When does Rua Life Sciences pay dividends?
Rua Life Sciences pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Rua Life Sciences?
Rua Life Sciences paid dividends every year for the past 0 years.
What is the dividend of Rua Life Sciences?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
In which sector is Rua Life Sciences located?
Rua Life Sciences is assigned to the 'Health' sector.
Wann musste ich die Aktien von Rua Life Sciences kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Rua Life Sciences from 8/27/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 8/27/2024.
When did Rua Life Sciences pay the last dividend?
The last dividend was paid out on 8/27/2024.
What was the dividend of Rua Life Sciences in the year 2023?
In the year 2023, Rua Life Sciences distributed 0 GBP as dividends.
In which currency does Rua Life Sciences pay out the dividend?
The dividends of Rua Life Sciences are distributed in GBP.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Rua Life Sciences
Our stock analysis for Rua Life Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Rua Life Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Rua Life Sciences Revenue
- Rua Life Sciences Net Income
- Rua Life Sciences P/E
- Rua Life Sciences P/S
- Rua Life Sciences EBIT
- Rua Life Sciences Dividend
- Rua Life Sciences Stocks
- Rua Life Sciences Market capitalization
- Rua Life Sciences Debt
- Rua Life Sciences Liabilities
- Rua Life Sciences Equity
- Rua Life Sciences AAQS
- Rua Life Sciences Employees
- Rua Life Sciences ROE
- Rua Life Sciences ROA
- Rua Life Sciences ROCE
